Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medium-chain triglycerides + long-chain triglycerides is a combination lipid emulsion used primarily as a source of calories and essential fatty acids in patients requiring parenteral nutrition when oral or enteral feeding is not possible, insufficient, or contraindicated. The formulation combines the rapid metabolism and easy absorption of medium-chain triglycerides (MCTs) with the essential fatty acid content of long-chain triglycerides (LCTs). This combination provides an efficient energy source for critically ill patients and those with malabsorption syndromes. In clinical use, these emulsions are found to be safe and effective for providing nutritional support in various patient populations including neonates, adults with gastrointestinal disorders, critically ill patients in intensive care units, and those recovering from surgery. The mechanism involves supplying readily oxidizable fatty acids (from MCTs) for quick energy production while LCTs provide essential fatty acids necessary for physiological functions[1][3][4][6]. Some formulations are also used as vehicles for intravenous drugs such as propofol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on medium-chain triglycerides + long-chain triglycerides.